Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study

• DOI: 10.1007/s00415-019-09337-6
• Publication Date: 2019-05-27T11:02:45Z
• Authors: Leonardo Lopiano; Nicola Modugno; Pietro Marano; Mariachiara Sensi; Giuseppe Meco; Paolo Solla; Graziano Gusmaroli; Filippo Tamma; Francesca Mancini; Rocco Quatrale; Roberta Zangaglia; Annarita Bentivoglio; Roberto Eleopra; Giuliana Gualberti; Gabriella Melzi; Angelo Antonini
• Keywords: Neuroradiology; Movement Disorders

The GREENFIELD observational study assessed the effect of levodopa/carbidopa intestinal gel (LCIG) on motor and non-motor symptoms, related impact patient quality life caregiver burden up to 8 years. Final results a large Italian cohort patients who started LCIG in routine care between 2007 2014 are presented. Comparison baseline (before LCIG) follow-up visits yearly basis (visit 2/3) is reported. Primary endpoint was Unified Parkinson’s Disease Rating Scale (UPDRS-IV) Item 39; secondary endpoints were UPDRS I II, dyskinesia items, PD Quality Life Questionnaire-39, Sleep Scale-2, Gait Falls Questionnaire, Questionnaire Impulsive Disorders, Relative Stress Scale. Overall, 145 from 14 centers with mean time since start 2.8 ± 1.7 years at visit 2. UPDRS-IV item 39 score showed significant reductions compared (mean 2.0 0.81) 2 0.9 0.69; − 55%; p < 0.001) 3 1.0 0.75; 50%; 0.001). At 3, observed for duration (− 28%; 0.001), disability 40%; painful 40 (27.6%) experienced 49 serious adverse events which considered PEG/J procedure or device 16.3% cases. this support long-term efficacy symptoms as well activities daily living. consistent established safety profile.